- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03800693
2 versus 6 timers oksaliplatin-infusjoner hos pasienter med gastrointestinale kreftformer
Fase II-evaluering av effekten av 2 versus 6-timers oksaliplatin-infusjoner på nevropati og farmakokinetikk hos pasienter med gastrointestinal kreft
This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine the effect of 2 versus 6-hour oxaliplatin infusion time on the difference in severity of sensory neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale at the initiation of cycle 4.
SECONDARY OBJECTIVES:
I. Pharmacokinetic parameters of maximum concentration (Cmax), area under the curve (AUC), time of maximum concentration (tmax), clearance, and half life (t1/2) of platinum ultra-filtrate.
II. CIPN-20 sensory score changes over the duration of therapy as measured by a cumulative area-under-the curve score.
III. Clinical outcomes including duration of therapy, oxaliplatin dose reductions, delays in therapy, and overall dose intensity and delivery of oxaliplatin.
IV. Relationship between oxaliplatin Cmax, patient-reported acute neurotoxicity, and chronic neurotoxicity by CIPN-20 scores.
OUTLINE: Patients are randomized to 1 of 2 groups.
2-hour infusion group: Patients receive oxaliplatin intravenously (IV) and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
6-hour infusion group: Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1, 3, 6, 12, and 18 months.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Amber Draper, PharmD
- E-post: amber.draper@emoryhealthcare.org
Studer Kontakt Backup
- Navn: Olumide B. Gbolahan, MBBS, MSc
- Telefonnummer: 404-778-0032
- E-post: ogbolah@emory.edu
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Ta kontakt med:
- Allyson Anderson
- Telefonnummer: 404-686-0239
- E-post: allyson.anderson@emory.edu
-
Hovedetterforsker:
- Olumide B. Gbolahan, MBBS, MSc
-
Atlanta, Georgia, Forente stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Ta kontakt med:
- Allyson Anderson
- Telefonnummer: 404-686-0239
- E-post: allyson.anderson@emory.edu
-
Hovedetterforsker:
- Olumide B. Gbolahan, MBBS, MSc
-
Atlanta, Georgia, Forente stater, 30342
- Rekruttering
- Emory Saint Joseph's Hospital
-
Hovedetterforsker:
- Olumide B. Gbolahan, MBBS, MSc
-
Ta kontakt med:
- Kathleen M. Coleman
- Telefonnummer: 404-251-1278
- E-post: kathleen.marie.coleman@emory.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Confirmed diagnosis of a gastrointestinal cancer
- Plan for 4 or more cycles of FOLFOX6 (fluorouracil [with leucovorin] and oxaliplatin) containing chemotherapy
- Histologically confirmed, measurable or evaluable disease. Patients with advanced or metastatic disease should have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients in the adjuvant treatment setting planned to have > 4 cycles of FOLFOX-containing chemotherapy are eligible and will be followed per standard of care
- Absolute neutrophil count (ANC) ≥ 1,500/µL (no white blood cell growth factors allowed to meet requirement)
- Platelets ≥ 75,000/µL (may be transfused up to 72 hours prior to day 1 to meet requirement)
- Hemoglobin ≥ 8 g/dL (may be transfused up to 72 hours prior to day 1 to meet requirement)
- Creatinine clearance > 30 mL/min by Cockcroft-Gault, to preserve similar dosing (85 mg/m²) for analysis
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Signed informed consent
- Adequate birth control when appropriate
Exclusion Criteria:
-
Any preexisting grade 2 or higher peripheral neuropathy
-
Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6
-
Known intolerance or hypersensitivity to any agent in FOLFOX6 or concurrent agents
-
Patients who have any known severe and/or uncontrolled medical conditions such as:
- Unstable angina pectoris, symptomatic heart failure; (New York Heart Association class III or IV), myocardial infarction ≤ 6 months prior, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
- Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, or decompensated liver disease
-
Patients with any history of severe hemorrhage requiring ≥ 4 units of packed red blood cells (RBCs) in a 48-hour period
-
Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
-
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing
-
Pregnant or nursing (lactating) women
-
Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include combination of any two of the following:
- Use of oral, injected or implanted hormonal methods of contraception or;
- Placement of an intrauterine device (IUD) or intrauterine system (IUS);
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
- Total abstinence or;
- Male/female sterilization Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: 2-hour infusion group
Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
|
|
Eksperimentell: 6-hour infusion group
Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale
Tidsramme: Baseline up to 60 days (course 4)
|
The EORTC-CIPN-20 sub-scales will be computed according to the standard scoring algorithm and then transformed to a 0 to 100 scale, where high scores mean less symptom burden. The primary outcome measure of difference in sensory scores of the two groups between baseline and the initiation of cycle 4 will be the driver of the analysis. |
Baseline up to 60 days (course 4)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum concentrations achieved (Cmax)
Tidsramme: At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin
|
The study will focus on maximum concentrations achieved (Cmax) with each infusion time. Data will be analyzed using non-compartmental methods via Phoenix WinNonlin analytical software, version 8.0 or higher. |
At baseline and at 1, 2, 4, 6, 48, and 192 hours after initiation of oxaliplatin
|
|
Changes in tumor size
Tidsramme: Up to 18 months after completion or discontinuation of chemotherapy
|
The study will assess changes in tumor size per standard of care assessments at screening and every 2 months. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Duration of therapy
Tidsramme: Up to 18 months after completion or discontinuation of chemotherapy
|
Duration of therapy will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Dose density
Tidsramme: Up to 18 months after completion or discontinuation of chemotherapy
|
Dose density will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
|
Frequency of dose holds or reductions
Tidsramme: Up to 18 months after completion or discontinuation of chemotherapy
|
Frequency of dose holds or reductions will be recorded. |
Up to 18 months after completion or discontinuation of chemotherapy
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Olumide B. Gbolahan, MBBS, MSc, Emory University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Gastrointestinale neoplasmer
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Enzymer og koenzymer
- Koordinasjonskomplekser
- Pyrimidiner
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folsyre
- Pteriner
- Pteridiner
- Uracil
- Pyrimidinoner
- Koenzymer
- Oksaliplatin
- Fluorouracil
- Leucovorin
Andre studie-ID-numre
- IRB00106610
- NCI-2018-02241 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- Winship4468-18 (Annen identifikator: Emory University Hospital/Winship Cancer Institute)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .